Drugs / Albumin 20%
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT01561053 | Apr 2012 → Mar 2018 | Alzheimer disease | Grifols, S.A. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Albumin 20% | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01561053 ↗ |
| Modality | Protein / enzyme biologic | “Biological: Albumin 20%” NCT01561053 ↗ |